Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial)

BACKGROUND: Cancer cachexia is a major cause of morbidity and mortality with no widely approved treatment. METHODS: The ACT‐ONE trial is a randomized, double‐blind, parallel group, placebo‐controlled, phase II multicentre trial in patients (25‐80 years) with stages III or IV colorectal cancer or non...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart Coats, Andrew J., Ho, Gwo Fuang, Prabhash, Kumar, von Haehling, Stephan, Tilson, Julia, Brown, Richard, Beadle, John, Anker, Stefan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929828/
https://www.ncbi.nlm.nih.gov/pubmed/27386169
http://dx.doi.org/10.1002/jcsm.12126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929828/
https://www.ncbi.nlm.nih.gov/pubmed/27386169
http://dx.doi.org/10.1002/jcsm.12126

Ejemplares similares